Mumbai, April 17 -- The drug is intended for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults.

Developed by the Venus Medicine Research Centre (VMRC)-the R&D arm of Venus Remedies-VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate. It has been designed specifically to mitigate the nephrotoxic effects often associated with conventional polymyxin B therapy, a critical concern in treating drug-resistant infections.

The QIDP status has been granted under the Generating Antibiotic Incentives Now (GAIN) Act, a U.S. initiative aimed at encouraging the development of new antibiotics to combat serious or life-threatening infections. With this designation, VRP-034 ...